Skip to main content

International Psoriasis Council

Advancing Knowledge. Improving Care.

Shining a Spotlight on our 2022 Fellows: Get to Know the Future Leaders in Psoriasis – Natalia Merino, MD

Natalia Merino, MD

Hospital Nacional Edgardo Rebagliati

Lima, Peru

IPC Jr. Councilor

Bio
Can you tell us briefly about your background and what led you to apply for this program?

In the early stages of my medical residency, I found myself particularly drawn to the dermatology field; within it, I developed a deep fascination for psoriasis. After completing my specialty, I sought ways to specialize further in this field. When I discovered the IPC International Fellowship Program, I recognized it as the perfect opportunity to enhance my knowledge and further explore my passion for psoriasis management.

How has this program helped you grow personally and professionally?

Being a part of this fellowship has been an incredible boost to my dermatology career. It provided me access to experienced professionals in psoriasis management and exposed me to global clinical research in this field.

“The IPC International Fellowship stands out by providing theoretical classes and facilitating interactions with other passionate dermatologists specializing in psoriasis. This creates a rich and supportive community that encourages growth and learning together.” 

How has the program prepared you for your future career goals?

IPC’s Fellowship Program has been crucial in laying a solid foundation for my future career aspirations. The well-structured curriculum encompassed a diverse range of topics related to psoriasis management. Expert-led classes familiarized me with the latest treatments and instilled in me a comprehensive approach to handling unique and challenging scenarios. Additionally, my participation in co-mentoring groups proved to be an eye-opening experience. Through these groups, I gained invaluable insights into managing psoriasis in patients with cardiovascular disease and chronic infections. These learnings have undoubtedly prepared me to confidently face future challenges in my practice.

Can you share a specific project or accomplishment you're proud of from your time in the program?

During my fellowship, I had the honor of collaborating with Dr. Claudia De la Cruz, MD, from Chile. Together, we initiated a study on psoriasis epidemiology in Peru, addressing the country’s lack of current data. Our survey aims to bridge this gap, providing valuable insights to enhance patient care and psoriasis management. Currently, we are diligently conducting the survey for this purpose.

How has the program fostered collaboration and networking among IPC Board, Councilors, and Fellows?

The IPC fosters collaboration and networking by involving Fellows and the IPC community in their numerous clinical research projects. This allows the Fellows to remain actively engaged in the field of psoriasis.

IPC’s Fellowship Program fosters collaborations and networking among IPC Fellows, Board Members, and Councilors. Through IPC’s multitude of clinical research projects, all members of the community, including Fellows, are encouraged to actively participate in topics that align with their interests and expertise. This inclusive approach facilitates valuable collaborations and ensures that we remain at the forefront of developments in the dynamic world of psoriasis management.

Can you describe the mentorship and support you've received from the program faculty, IPC staff, and other IPC Fellows?

The mentorship and support I received during the fellowship have been instrumental in shaping my journey. I was fortunate to have Dr. Claudia de la Cruz from Clinica Dermacross in Chile as my mentor during the fellowship. Together, we initiated the psoriasis survey in Peru. Additionally, I built strong connections with other exceptional Fellows from Latin America and across the globe, providing an invaluable network for psoriasis projects. The entire IPC community is incredibly supportive and friendly.

What advice would you give to someone considering applying for this program?

If you are considering applying for the IPC Fellowship Program, I wholeheartedly recommend it. The benefits of this program extend far beyond the classroom and research projects. By joining this program, you will be granted access to some of the world’s most esteemed experts in psoriasis management. The exposure and connections you gain will prove to be transformative for your career.

In what ways do you think this program is unique and sets itself apart from other programs?

The IPC International Fellowship stands out by providing theoretical classes and facilitating interactions with other passionate dermatologists specializing in psoriasis. This creates a rich and supportive community that encourages growth and learning together. The program also goes beyond the fellowship duration; it enables lasting connections with IPC and mentors, ensuring a continuous exchange of knowledge and support. Lastly, the program’s emphasis on attending meetings and visiting mentors adds a practical and hands-on dimension to the learning process, which I believe is crucial for a holistic understanding of psoriasis management. Undoubtedly, it’s an excellent platform to continue growing as a dermatologist.

If you are a young dermatologist or researcher that is passionate about improving the lives of people with psoriasis and wants to expand your horizons, consider applying to participate in the IPC’s International Fellowship Program. Applications for the 2024 program will open this September.

Categories

Recent Posts

When Cancer and Psoriasis Coexist: New IPC Guidance Puts Clarity Where It Is Needed Most

Reframing Obesity in Psoriatic Disease: From Pharmacokinetic Barrier to Therapeutic Target

Psoriasis and Metabolic Health: What IPC’s Latest Publication Means for Clinical Practice

Also Read

Subscribe to the IPC Newsletter

Stay up-to-date on the latest research, news, and upcoming events right in your inbox.

What's New

When Your Patient with Psoriasis Is Diagnosed with Cancer

A patient doing well on an IL-17 inhibitor is diagnosed with cancer, and the oncologist wants the biologic stopped. It is a call most dermatologists have made without much to stand on: patients with cancer are excluded from psoriasis trials, so the entire evidence base is observational. A new IPC paper in JAAD Reviews takes a position anyway. Per the summary of product characteristics, active malignancy is not a contraindication to any biologic. IL-17 and IL-23p19 inhibitors are first-line, TNF inhibitors and deucravacitinib warrant caution, and cyclosporine is the one to avoid outright. The authors also warn that psoriasis severity is routinely underestimated once a patient is in oncology care: if they meet IPC’s criteria, they are a candidate for systemic therapy regardless of what else is on their problem list. “Too often, systemic psoriasis therapy is discontinued or never initiated in patients with cancer, even when the evidence supports safe and effective options,” says Paolo Gisondi, MD, IPC Councilor and lead author. The post includes the therapeutic options figure, designed as a reference for both specialties to work from, and a slide set for teaching and presentations.

READ NOW

Thursday, August 27, 2026

Apply Now: 2027 IPC International Fellowship Program

IPC is accepting applications for the 2027 International Fellowship Program, a 12-month opportunity for early-career dermatologists and researchers focused on psoriasis. Fellows are matched with IPC Board Members or Councilors for hands-on clinical or research experience, along with virtual mentoring, skills-development classes, and ongoing connections to IPC’s global network throughout the fellowship year. Applications are open until September 30, 2026.

APPLY NOW

Monday, August 31, 2026

IPC Generalized Pustular Psoriasis (GPP) Training Modules

Recognizing GPP in clinical practice can be a challenge, even for experienced dermatologists. IPC’s new five-part training series walks clinicians through the practical skills needed to diagnose and assess GPP with confidence: distinguishing it from plaque psoriasis and other mimicking conditions, and scoring its severity using tools such as the GPPGA and GPPASI. Each module pairs an expert-led video with a case-based exercise, and the series is built to be completed in sequence at your own pace. All five modules are free and open to everyone; watch the videos on your own or work through the assessments as you go. Score 80% or higher on each of the five assessments to earn a Certificate of Completion.

LEARN MORE

Thursday, August 13, 2026

IPC Summary Slides: Psoriasis and Metabolic Health

IPC has released a set of summary slides distilling the key findings from its recent publication on psoriasis and metabolic health, published in the Journal of the American Academy of Dermatology (JAAD). The paper outlines five priorities for improving cardiometabolic risk screening and care in patients with psoriasis. Designed for sharing, the slides give clinicians and colleagues an easy way to disseminate the findings.

LEARN MORE

Wednesday, August 5, 2026

Paradoxical Psoriasis - María Julia Cura, MD

In this Take Ten with IPC video, IPC Junior Councilor Dr. María Julia Cura discusses paradoxical psoriasis, including its definition and pathogenesis, and reviews clinical case examples, key clinical features, histopathology, predictors of disease severity, and potential treatment options.

WATCH NOW

Monday, August 3, 2026